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Summary
Yin and Yang are two complementary forces that together describe the nature of real world
elements. Yin is the dark side; Yang is the light side. We describe microRNAs having both Yin
and Yang characteristics, because they can contribute to normal function (Yang) but also to
autoimmunity, myeloproliferation, and cancer (Yin). We have been working on a number of
microRNAs that have these dual characteristics and here we focus on two, miR-125b and
miR-146a. We have concentrated on these two RNAs because we have very extensive knowledge
of them, much of it from our laboratory, and also because they provide a strong contrast: the
effects of overexpression of miR-125b are rapid, suggesting that it acts directly, while the effects
of miR-146a are slow to develop suggesting that they arise from chronic alterations in cellular
behavior.
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Introduction
MicroRNA-125b (miR-125b) is the mammalian homolog of the C. elegans heterochronic
microRNA lin-4 (1), which is essential for normal temporal development of C. elegans (2).
In mammalian systems, the mature sequence of miR-125b is encoded in two different
genomic regions: miR-125b-1 is located in chromosomes 11 and 9, respectively, in the
human and mouse genomes, and it is human chromosome 21 and mouse16 for miR-125b-2.
In addition to miR-125b-1 and miR-125b-2, the mammalian genome encodes the homolog
miR-125a, which shares an identical seed sequence with miR-125b. Although the functional
role of lin-4 in C. elegans has been studied extensive since its discovery over three decades
ago (3), the study of miR-125b’s functions in mammals is just beginning. Knockout mice
models for miR-125b-1, miR-125b-2, and miR-125a are not currently available, thus
limiting the ability to study the individual physiological roles of the miR-125 family. Thus,
we applied a loss-of-function miR-125b ‘sponge’ decoy system, which implicated the role of
miR-125b in hematopoiesis. Overexpression systems have provided the best clues to
miR-125b functions. These gain-of-function systems constitutively overexpress miR-125b
and thereby perturb its normal regulated expression. By observing changes in biological
process upon such perturbation, these studies provide clues to the function of miR-125b.
From these studies, miR-125b has been shown to be important for normal hematopoiesis by
modulating cell proliferation and differentiation. In contrast, abnormal and unregulated
overexpression of miR-125b leads to accelerated hematopoiesis that subsequently leads to a
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rapid and acute leukemia. Here, we review recent advances in understanding the functional
role of miR-125b in hematopoiesis and its pathological role in leukemogenesis.
MicroRNA-146a (miR-146a) and miR-146b form a highly conserved two-member miRNA
family. miR-146a and miR-146b are located on chromosome 5 and 10, respectively, in the
human genome and on chromosome 11 and 19, respectively, in the mouse genome. In 2006,
miR-146a first came to our attention in a systemic microarray screen to identify miRNAs
that are involved in innate immune activation (4). Stimulating THP1 cells, a human
monocytic cell line, with lipopolysaccharide (LPS) was found to selectively upregulate the
expression of three miRNAs, miR-155, miR-146, and miR-132. Since then, we have been
focused on investigating the function of miR-146 and miR-155 in the immune system. To
study the physiological role of miR-146a, we generated miR-146a knockout mice to disrupt
miR-146a function in these animals. By ablating miR-146a function, we and other
researchers gained extensive knowledge on the role of miR-146a in the immune system. We
found that miR-146a orchestrates myeloid and lymphocyte function thus impacting both
innate and adaptive immunity. Whereas overexpression of miR-125b induces leukemia in
mice, the deletion of miR-146a leads to hematopoietic malignancy. In contrast to miR-125b,
frank cancer in miR-146a-ablated mice develops in older mice, suggesting that the effect
results from chronic alterations and may require longer-term accumulation of cellular
abnormalities to induce tumorigenesis. Here, we review the recent findings on role of
miR-125b and miR-146a in leukemogenesis and hematopoiesis, the yin and yang of these
microRNAs.
The Yang of miR-125b: function in hematopoietic development and
immunity
Expression patterns of miR-125 in hematopoietic lineages
Our laboratory has been studying a variety of microRNAs, mainly ones induced by the NF-
kB transcription factor. However, our attention was drawn to miR-125b in experiments
designed to examine the role of miRs in the regulation of hematopoietic stem cell (HSC)
development. These experiments involved performing microarray analysis to identify
microRNAs enriched in hematopoietic stem-progenitor cells (HSPCs) (5). Compared to total
bone marrow cells isolated from adult mice, we found 11 microRNAs to be enriched in
HSPCs (defined as Lin−Sca1+cKit+). Of particular interest, four of these non-coding RNAs
belonged to the group in the highly conserved microRNA cluster miR-125/miR-99/Let-7.
The mouse genome encodes three separate clusters of these microRNAs: (i) miR-125a/
miR-99b/Let-7e, (ii) mir-125b-2/miR-99a/Let-7c-1, and (iii) miR-125b-1/miR-100/let-7a-2.
In our study, we found that miR-125b, miR-125a, miR-99a, and Let-7e were preferentially
expressed in HSPCs and long-term HSCs compared to total bone marrow cells (5). The
expression of miR-125b, miR-125a, and miR-99a is lower in hematopoietic progenitor cells
(Lin−Sca1−cKit+ cells) compared to HSC and even lower in differentiated CD11b+ cells (5).
In a separate unbiased profiling study, Ooi et al. (6) also demonstrated that the expression of
miR-125b, miR-99a, and miR-100 was high in stem cells and became progressively reduced
as cells become more differentiated. The expression level of these microRNAs was reported
as follows: HSCs > multiple-potent progenitors (MPPs) > common myeloid progenitors
(CMPs) > granulocyte-macrophage progenitors (GMPs) > megakaryocytic-eythroid
progenitors (MEPs) (6). In a later study, Gerrits et al. (7) also performed microRNA
expression studies and found that miR-125b-5p, miR-125a-5p, miR-99b, miR-99a, and
Let-7e were expressed more highly in HSPCs compared to differentiated hematopoietic
cells. Collectively, these studies indicated that some members of the miR-125/miR-99/Let-7
cluster are preferentially expressed in HSCs and their levels tend to decrease as these cells
become more differentiated.
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miR-125 provide a hematopoietic repopulating advantage to hematopoietic stem cells The
progressive downregulation of microRNAs belonging to the miR-125/miR-99/Let-7 cluster
as cells become more differentiated led us and other research groups to hypothesize that
some members of this cluster might play a role in hematopoiesis at the HSC level. To
address this hypothesis, we investigated whether the four microRNAs belonging to this
family, which were highly expressed in HSCs (miR-125b, miR-125a, miR-99a, and Let-7e),
modulate hematopoiesis (5). We performed competitive repopulation experiments by
populating lethally irradiated recipient mice with combined populations of HSC-enriched
CD45.1+ bone marrow cells that over-express these microRNAs and control HSC-enriched
CD45.2+ cells. Whereas miR-125b overexpression conferred a competitive repopulation
advantage as compared to control cells, miR-99a and Let-7e overexpression were
disadvantageous to engraftment (5). These microRNAs affected hematopoiesis in multiple
lineages, consistent with these molecules having an effect on stem cell homeostasis (5). A
similar study of mice by Ooi et al. (6) reported that purified Lin−cKit+Sca1+CD34−Flk2−
HSCs overexpressing miR-125b also exhibited enhanced repopulation potential compared to
control HSCs. In addition, Guo et al. (8) and Gerritis et al. (7) showed that restricted
overexpression of the miR-125a/miR-99b/Let-7e cluster or miR-125a alone in bone marrow
cells also elevated the ability of these cells to repopulate the hematopoietic compartment of
mice. Further analyses revealed that miR-125a provided self-renewing capacity specific to
HSCs but not for CLPs, CMPs, GMPs, or MEPs, showing that the effect of miR-125a is cell
specific and depends on the differentiated stage of the cells (8). In contrast to our study (5),
Guo et al. (8) did not observe a disadvantage in repopulation upon Let-7e overexpression;
the discrepancy may be due to differences in expression levels Let-7e. Thus, members of the
miR-125/miR-99/Let-7 control hematopoiesis in part by affecting function at the HSC-level.
In particular, the miR-125 family seems to provide an advantage for stem cells to repopulate
(Fig. 1A). However, the role of miR-99 and Let-7 members will require further analyses.
The functions of miR-125b and miR-125a in all the studies described above were inferred
from non-physiological over-expression systems. To provide insights into the physiological
function of miR-125b and miR-125a in hematopoiesis, we utilized a ‘sponge decoy’ to
competitively inhibit miR-125b and miR-125a binding to its natural targets (9). The
recipient mice reconstituted with sorted miR-125-sponge transduced bone marrow cells had
significantly fewer white blood cells (CD45+), myeloid cells (CD45+CD11b+), pre-
erythrocytes (CD45+Ter119+), and granulocytes (CD45+Gr1+) compared to the controls one
month after reconstitution (9). The miR-125 sponge loss-of-function experiments indicated
an important physiological role for miR-125 in hematopoiesis and potentially stem cells
since inhibiting miR-125 function affected the development of multiple lineages. Because
the sponge decoy targets both miR-125b and miR-125a, further experiments will be required
to determine which microRNA regulates these processes.
The role of miR-125b in development of myeloid and lymphoid cells
In addition to being able to impact stem cell repopulation, overexpression of miR-125b in
the bone marrow can lead to a myeloid or lymphoid bias. Using an MSCV-based retroviral
delivery system, we transduced HSPC-enriched cells from mouse adult bone marrow with a
miR-125b overexpression cassette. These cells were transplanted into lethally irradiated
recipient mice. The primary recipient mice that overexpressed miR-125b had a dramatic
increase in all myeloid lineages, including granulocytes, macrophages, and dendritic cells (5,
9). Importantly, B-cell numbers were significantly decreased in these animals. Similarly,
pre-B and pro-B-cell numbers were severely decreased, indicating that the repression of B-
cell development occurred at the progenitor stage. However, the numbers of the more
upstream common lymphoid progenitors (CLPs) were significantly upregulated, suggesting
that miR-125b overexpression caused a developmental block between the CLP and pro-B-
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cell stages (Fig. 1B). Moreover, miR-125b likely can also block B-cell development at the
pre-B-cell stage. Puissegur et al. (10) showed that miR-125b directly repressed the
expression of Bright/Arid3a, an activator of immunoglobulin heavy-chain transcription, and
blocked the differentiation of murine pre-BI cells to B cells. In addition to inhibiting the
development of B cells at early progenitor stages, miR-125b can block the maturation of B
cells to plasma cells. Upon overexpressing miR-125b in primary B cells, Gururajan et al.
(11) found that it impaired the LPS induction of these cells into CD19loCD138hi plasma
cells. It was hypothesized that miR-125b might inhibit plasma cell differentiation by directly
repressing the expression of B-lymphocyte maturation protein-1 (BLIMP-1) and interferon
(IFN) regulatory factor-4 (IRF4), factors important for plasma cell generation (11). In
support of our data that miR-125b favors myeloid development, Klusmann et al. (12)
showed that transduction of miR-125b-2 into adult murine bone marrow and human CD34+
HSPCs elevated the absolute number of myeloid colony-forming units (CFUs) in vitro. In
agreement with our miR-125b studies, Gerritis et al. (7) showed that primary transplant
recipients of HSPCs transduced with a miR-125a overexpression vector displayed an
enrichment of myeloid cells accompanied by a decrease in B cells. Together, these studies
showed that miR-125b and miR-125a are capable of expanding the myeloid compartment at
the expense of B cells and can block B-cell genesis at multiple stages of development.
Ooi et al. (6) performed secondary transplant studies in which recipient mice received
Lin−Sca1+cKit+CD34−Flk2− HSCs overexpressing miR-125b from primary recipients. In
contrast to our primary transplant experiments, these mice exhibited increased chimerism
within the preproB- and pro-B population in the spleen. The secondary transplanted mice
also had higher chimerism within the CD4+ and CD8+ T-cell population in the lymph nodes.
The increase in lymphoid cells in these mice could be explained by these mice having
statistically significant higher percentage of Slamf1loCD34− and Slamf1−CD34− cells,
which possess a lymphoid biased cell output (6). Perhaps, in the primary recipient of bone
marrow cells, the lack of B cells leads to selection for a stem cell population that tries to
augment the output of B cells. Whatever the case may be, enforced expression of miR-125b
clearly generates a myeloid bias at the expense of B cells in primary transplants, although it
also can lead to expanded populations of lymphoid cells in secondary transplants.
In addition to myeloid and B-cell development, Rossi et al. (13) reported a role of miR-125b
in regulating the differentiation of naive CD4+ T cells to effector cells. In an effort to
identify distinct microRNA signatures of human T-cell lymphocytes subsets, the authors
found that miR-125b was highly expressed in naive CD4+ T cells compared to memory T
cells. They identified targets of miR-125b in human cells and showed that it regulates a
panel of genes involved in T-cell differentiation, such as IL2RB and PRDM1. Following
transfection of a miR-125b-mimic, the differentiation of naive CD4+ T cells to effector T
cells was blocked and, as well, there was a decreased expression of memory cell markers
CXCR3 and CCR4 (Fig. 1C). Moreover, ectopic expression of miR-125b also affected the
responsiveness of T cells. Overexpression of miR-125b inhibited the production of
interleukin-13 (IL-13) and IFNγ upon stimulation with phorbol 12-myristate 13-acetate plus
ionomycin (13). In addition to a cellular function of miR-125b in T cells, miR-125b also
contributes to HIV-1 viral production and latency in these cells (14). HIV enters latency in
resting CD4+ T cells in patients under antiretroviral therapy, allowing replication-competent
HIV to be maintained in these cells, and thus allowing HIV to escape eradication by
antiretroviral therapy (15–17). Huang et al. (14) demonstrated that inhibition of miR-125b
along with miR-28, miR-150, miR-223, and miR-382 elevated HIV-1 production in resting
CD4+ T cells but not in activated CD4+ T cells. miR-125b directly binds to the 3′UTR of
HIV-1, thereby suppressing expression and viral production. This suggested that miR-125b
might be utilized by HIV-1 to remain in latency in resting CD4+ T cells. This finding
highlighted the possibility that inhibiting miR-125b along with miR-28, miR-150, miR-223,
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and miR-382 could be a method for eradication of the latent HIV-1 that escapes
antiretroviral therapy (14). Thus, miR-125b is important for cellular T-cell function by
modulating differentiation of naive T cells but also is important for controlling HIV-1 viral
production and latency in these cells.
miR-125b modulates macrophage function
In an effort to further understand the role of miR-125b in hematopoiesis and immunity, we
investigated the expression of miR-125b in different immune cells/tissues and found that
miR-125b was much higher in macrophages compared to total splenocytes, thymocytes,
splenic T cells, splenic B cells, and peritoneal macrophages from C57Bl/6 mice (18). To
investigate the functional role of miR-125b in macrophages, we overexpressed miR-125b-1
(~15-fold) in bone marrow-derived macrophages (BMMs). Interestingly, miR-125b-1
overexpressing BMMs acquired a spread morphology that resembled activated
macrophages. The activated status of these cells was confirmed by flow cytometric analyses,
revealing an elevated expression level of macrophage activation markers, major
histocompatibility complex class II, CD40, CD86, and CD80 (18). Augmented expression of
miR-125b in terminally differentiated RAW264.7 macrophages gave similar results, further
emphasizing that this microRNA promotes activation of macrophages. The heightened
activation status may in part be due to miR-125b-1 suppressing its direct target IRF4.
Knocking down IRF4 expression using RNAi recapitulated the effect of miR-125b-1
overexpression in macrophages, leading to increased surface expression of activation
markers major histocompatibility complex class II, CD40, CD86, CD80, and IFNγR.
Moreover, miR-125b-1 overexpressing BMMs also expressed higher levels of cell surface
IFNγR, resulting in a heightened responsiveness of these cells to IFNγ stimulation. In
addition to miR-125b-1 driving an elevated activation status and a hyperresponsiveness to
stimulatory cues in macrophages, it also potentiated macrophage-mediated immune
function. We showed that enforced augmented expression of miR-125b elevated the ability
of macrophages to act as effective antigen-presenting cells for stimulating T cells in vitro
(18). The effectiveness of miR-125b-stimulated macrophages at killing tumor cells was also
assessed. miR-125b overexpressing macrophages were more effective at inducing apoptosis
of the EL4-Fluc thymoma cell line in vitro. Macrophages with miR-125b ectopic expression
were more effective in suppressing the ability of EL4 thymoma cells to expand in vivo when
equal numbers of control or miR-125b overexpressing macrophages were co-injected with
the cancer cells into mice (18). Our experiments thus provided evidence that miR-125b
could modulate the activation status, responsiveness, and function of macrophages.
miR-125b:Lin28A axis
We are left with a reasonably clear picture of the function of miR-125a and miR-125b in the
differentiation of HSCs into their downstream cell types. Clearly, miR-125 overexpression is
able to potentiate the growth of HSCs and a sponge for miR-125 (and other miRs with the
same seed sequence) can disadvantage HSCs, arguing that one function of miR-125 is to
augment the HSC pool. As cells begin to differentiate away from the HSC stage, miR-125
appears to favor myeloid development and block B-lymphoid development, although
secondary transplant gives a somewhat different picture. Not only does miR-125 stimulate
commitment to the myeloid lineage, it also causes myeloid cells to adopt a more highly
activated phenotype while it appears to inhibit the B-cell lineage continually at main nodes
in their differentiation. The targets of miR-125 that allow it to have these disparate effects
on the two lineages remain to be definitively defined. Lin28 is a direct target of miR-125b;
the interaction between Lin28 and miR-125b is highly conserved from mammals to C.
elegans. In bone marrow reconstitution experiments, we found that knocking down Lin28A
resulted in an increased number of myeloid cells accompanied by a decrease in B cells in
mice (9). However, leukemia was not observed in these mice. This might be due to
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insufficient knockdown of Lin28A in the experiments or that tumorigenesis induced by
miR-125b is independent of Lin28A. Collectively, these data suggests that miR-125b might
modulate hematopoiesis in part by directly regulating the expression of Lin28A, but the role
of Lin28A in miR-125b-mediated leukemogenesis will require further experiments.
The Yin of miR-125b: its role as an oncomir in hematopoietic cells
Dysregulated expression of miR-125b in human leukemias
Because approximately 50% of microRNAs are located at fragile or cancer-associated
genomic regions in the human genome (19), it is no surprise that aberrant expression of
many different microRNAs has been observed in multiple cancer types. In particular, a
significant number of studies have shown that dysregulated expression of miR-125b is
correlated with human leukemia. Three studies separately reported a total of five patients
with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) harboring a genetic
aberration with insertion or translocation of miR-125b-1 into the immunoglobulin heavy
chain (IGH) locus (20–23). All three patients who were examined exhibited elevated
miR-125b-1 expression compared to normal controls (20, 22, 23). Also, patients with
myelodysplastic syndromes (MDS) who harbor t(2;11)(p21;q23) or 5q-exhibit increased
expression of miR-125b-1 compared to healthy subjects (up to 70-fold) (24–26). Similarly,
acute myeloid leukemic (AML) patients carrying t(2;11)(p21;q23) translocation or FLT3
mutation also have higher expression of miR-125b (24, 27). Overexpression of miR-125b
appears be specific to cytogenetically distinct subsets of adult AML, because it was not
found in patients harboring an NPM1 mutation (27). In pediatric AML patients, miR-125b is
also expressed at higher than normal levels, with the M3 subtype being the highest (on
average 200-fold) (28). Similarly, compared to normal CD34+ cells, miR-125b is also
specifically upregulated in acute megakaryoblastic leukemic (AMKL) and transient
leukemic (TS) patients with trisomy 21 (Down syndrome) but not AML FAB M5 patients
(12). The common upregulation of miR-125b in leukemias of different cell origin suggests
that it might serve as a cancer inducer or driver of cancer cells. However, some of these
correlation studies are measured with tissue samples containing mixed cell types. Thus,
whether the upregulation of miR-125b in leukemic patients is due to changes in the cell
populations or is cell intrinsic will require more in-depth investigation.
Tumorigenic properties of miR-125b overexpression in hematopoietic cells in vitro The
findings that miR-125b regulates hematopoiesis and is upregulated in leukemic samples
generated a strong desire in the cancer field to determine if miR-125b plays a role in cancer
development. Several in vitro studies supported the notion that miR-125b possesses
tumorigenic potential. Several groups found that overexpression of miR-125b in
hematopoietic cells generated cancers by inhibiting apoptosis, accelerating proliferation, and
inducing abnormal self-renewal in non-stem cells. Ooi et al. (6) found that miR-125b
directly repressed the anti-apoptotic genes Bmf and KLF13. The authors also found that
miR-125b overexpressing cKit+ cells were quite resistant to staurosporine-induced apoptosis
in vitro (6). Similarly, Puissegur et al. (10) showed that miR-125b overexpressing pre-B1
cells were also more resistant to apoptosis.
In addition to inhibiting apoptosis, constitutive miR-125b overexpression can accelerate
proliferation and self-renewal of hematopoietic progenitor cells. Upon overexpressing
miR-125b-2 in mouse fetal liver megakaryocytic progenitors (FL MPs), Klusmann et al.
(12) found that it increases the size and numbers of megakaryocyte colony forming units
(CFU-MKs) in vitro. This finding indicated that miR-125b-2 elevates the proliferative rate
of MPs, which is a feature of cancer initiation. Importantly, the authors demonstrated that
miR-125b elevated the re-plating efficiency of fetal liver progenitors in methylcellulose-
based assays stimulated with thrombopoietin, arguing that miR-125b confers an abnormal
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self-renewal property on these cells, a hallmark of tumorigenesis (12). However,
miR-125b-2 overexpression did not alter the differentiation potential of MP cells (12). It
appears that enforced miR-125b-2 expression gives a proliferative advantage to FL MPs
without interrupting their ability to differentiate. Moreover, the authors demonstrated that
suppressing the activity of miR-125b in AMKL cell lines reduced cell viability. This finding
suggests that some cancer cells are dependent for their viability on miR-125b expression,
providing a rationale for targeting miR-125b as a form of cancer treatment. In support,
downregulation of miR-125b in other types of cancer cells, e.g. HeLA, PC3, and Tera2
(embryonic carcinoma) cancer cell lines, also reduced cell growth (29). Collectively, these
cell culture models reveal that miR-125b overexpression in megakaryocytic progenitors
induces a growth advantage as well as a self-renewal capacity in FL MPs, providing a model
in which miR-125b displays its tumorigenic potential.
Mouse models demonstrated miR-125b is an oncomir
Using murine models, we and other groups have demonstrated that restricted overexpression
of miR-125b in the hematopoietic compartment induces leukemia. In bone marrow
reconstitution experiments, we found that long-term enforced expression of miR-125b in
mice leads to myeloproliferative disorder (MPD) or leukemia depending on the level of
expression (5). Mice that received bone marrow cells overexpressing miR-125b to a modest
level developed MPD characterized by increased absolute numbers of neutrophils and
monocytes in the peripheral blood after two months of reconstitution (5). At this time, the
bone marrow exhibited a mild expansion of myeloid cells, but they remained normal in the
spleen. However, recipient mice that were transplanted with cells overexpressing miR-125b
at a high level were myeloid-dominant in the bone marrow and spleens after two months of
reconstitution. After 3.5 months, the peripheral blood of these mice was dominated by
immature granulocytic and monocytic cells with a very high white blood cell count (5).
Shortly after, the mice developed leukemia, became moribund, and subsequently succumbed
to the disease. This demonstrated a dose-dependent ability of miR-125b to drive
pathological myeloid expansion (5). Strikingly, we found that constitutive overexpression of
miR-125a also caused mice to develop myeloid leukemia (9), further supporting the notion
that the miR-125 microRNA family is an oncomir in hematopoietic cells.
Similar to our findings, Bousquet et al. (30) also demonstrated that restricted overexpression
of miR-125b (~700-fold above normal) in the hematopoietic compartment caused leukemia
in mice. The authors overexpressed miR-125b in fetal liver cells of mice and then performed
bone-marrow reconstitution experiments. At 16 weeks after cell transplantation, the authors
found that the recipient mice had higher white blood cell counts in the peripheral blood (30).
The increase in white blood cell count was due to an increase in neutrophils, basophils,
eosinophils, monocytes, and lymphocytes. Within 12 to 29 weeks, the recipient mice that
received miR-125b overexpressing fetal liver cells developed a range of malignancies (30).
Some mice developed myeloproliferative neoplasm (MPN) characterized by excess
neutrophils in the blood with granulocytes dominating the bone marrow and spleen. A
population of the miR-125b overexpressing mice also developed B220+ B-cell leukemia
with dominance of lymphoblasts in the blood and spleen. Other mice exhibited T-cell
leukemia. Interestingly, Bousquet et al. (30) revealed that mice overexpressing high levels of
miR-125b (~1,500- fold) generally developed MPN whereas those that had lower over-
expression (~500-fold) exhibited T-cell leukemia. Similarly, Ooi et al. (23) also showed that
miR-125b overexpression in mice could cause lymphocytic leukemia. In secondary
transplant experiments, Ooi et al. (6) noticed that ~11% of the recipient mice that received
miR-125b overexpressing donor cells from primary transplant exhibited lymphoproliferative
disease that was characterized by splenomegaly, enlarged thymi, and expansion of CD8+ T
cells. Although the mechanism by which miR-125b drives leukemia remains largely un-
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investigated, the study by Enomoto et al. (21) supports an interpretation that miR-125b
induces tumors through a cell-intrinsic mechanism at least for B-cell neoplasm. In an effort
to examine the effect of the translocation of miR-125b into the IgH locus in human leukemic
patient, Enomoto et al. (21) generated transgenic (TG) mice that mimicked this fusion. The
authors generated Eu/miR-125b-TG mice that overexpressed miR-125b driven by the IGH
enhancer and promoter. They found that mice overexpressing miR-125b driven by the IGH
enhancer and promoter developed IgM− and IgM+ lethal B-cell malignancies, implying that
miR-125b can drive tumorigenesis of B cells through a cell-intrinsic mechanism.
Collectively, these mouse models emphasize that miR-125b is an oncomir capable of
inducing tumorigenesis in different hematopoietic cells, including myeloid, T, and B cells.
To better understand the mechanism by which miR-125b induces myeloid cancer, we
investigated the type of hematopoietic cells that are upregulated upon miR-125b
overexpression. We focused on myeloid cancer, because we did not observe T- or B-cell
malignancies in the primary transplant animals that overexpressed miR-125b in our bone
marrow reconstitution experiments. At seven weeks after reconstitution, before the onset of
overt leukemia, miR-125b overexpressing mice had drastic increases in all myeloid lineages,
including granulocytes, macrophages, and dendritic cells. To examine the developmental
stage at which miR-125b overexpression promotes myelopoiesis, we analyzed
hematopoietic stem and progenitor cell (HSPC) numbers in the bone marrow. We were
surprised to find that the numbers of HSCs were similar compared to control mice.
However, progenitors downstream of HSCs, including multipotent progenitors (MPPs),
common myeloid progenitors and granulocyte macrophage progenitors (CMP/GMPs), and
myeloid-erythroid progenitors (MEPs), were all significantly increased. The CMP/GMPs
were most drastically augmented compared to control mice. Thus, prior to the onset of
leukemic disease, miR-125b enhances the development of the myeloid lineage likely by
increasing the population of CMP/GMP (Fig. 1E). Since the number of HSCs were not
increased before overt cancer development, this led us to hypothesize that miR-125b-driven
leukemic development might not be through HSCs in our experimental settings. Recall that
we mentioned earlier that in a competitive repopulation experiment, we found that
miR-125b gave HSCs a competitive advantage. Here, we overexpressed miR-125b in most
stem cells and would not have seen such an advantage. However, we did not see the HSC
compartment expand, suggesting that as the rate of differentiation of the cells is such that an
increased pool of HSCs is not observed. These experiments indicate that overexpression of
miR-125b causes uncontrollable proliferation and/or abnormal self-renewing characteristics
in early stage differentiated myeloid progenitors that subsequently leads to leukemia.
Although miR-125 appears to have an important normal role in the life of the HSC,
overexpression of this microRNA can either lead to myeloid cell hyperplasia or to frank
leukemia, depending on the extent of overexpression. We see tumors within a few months of
transplantation, and other data suggests that the action of miR-125 is cell-intrinsic, so it is
likely that miR-125 is a true oncogene for many if not all of the downstream cell types
generated from the HSC.
The Yang of miR-146a: functions in immunity
Regulation of miR-146a expression
In the hematopoietic system, the expression of miR-146a is relatively low in progenitor cells
and increases modestly with maturation. However, in certain specialized cell types, such as
Ly-6Clo monocytes and epidermal Langerhans cells, miR-146a is constitutively expressed at
a high level (31, 32, http://www.immgen.org/). In addition, miR-146a expression is
upregulated upon stimulation of myeloid cells with microbial components and pro-
inflammatory cytokines. miR-146a is also stimulated upon activation of T cells with T-cell
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receptor antigens (33–35). Viral and fungal infection also induces miR-146a expression (36–
38).
Basal and induced expression of miR-146a is regulated by several important transcription
factors in immune cells. Our initial characterization of miR-146a promoter locus identified
two consensus NF-κB binding sites that were shown to be important in transcriptional
activation of miR-146a in myeloid cells in response to inflammatory stimulation; mutations
of these consensus sequences abolished the promoter activity in a luciferase reporter system
(4). Subsequent studies showed that downregulation of NF-κB activity chemically or
genetically inhibits basal and induced expression of miR-146a in macrophages and T cells,
confirming the role of NF-κB in regulating miR-146a expression (34, 36, 37). In addition to
regulation by NF-κB, expression of miR-146a is also regulated by lineage-dependent
transcription factors. During myeloid differentiation, PU.1 works together with NF-κB to
control the basal expression of miR-146a through dynamic occupancy at the promoter
region (32, 39). In lymphocytes, the lineage-specific regulation of miR-146a may be
fulfilled by other transcriptional factors, such as c-ETS (38, 40). In addition to
transcriptional activation, miR-146a expression may be repressed in a lineage-specific
manner. This was shown in the example of megakaryocyte differentiation, where PLZF
upregulation interacts with the miR-146a promoter to inhibit its expression (41). A more
extreme case involves global miRNA repression, including miR-146a, by the myc oncogenic
transcriptional factor during lymphomagenesis (42). One interesting observation suggests
estrogen can modestly downregulate miR-146a but not miR-146b in mouse splenic
lymphocytes. However, it is not clear from the study whether the effect of estrogen on
miR-146a expression is direct (43). Overall, basal miR-146a expression is regulated by a set
of lineage-dependent transcription factors in a cell-lineage specific manner. This basal level
can be further regulated in an activation-dependent manner by inducible transcription
factors, such as NF-κB.
In comparison to miR-146a, the regulation of miR-146b expression is less well understood.
Some previous reports on miR-146b expression were performed primarily with
hybridization-based methods, which may have not been specific enough to separate the
mature sequences of miR-146a and miR-146b because they only differ by one nucleotide.
Nevertheless, miR-146b seems also to be induced by pro-inflammatory cytokines and
dysregulated miR-146b expression is associated with several human non-hematologic
cancers (44–49). In addition, in unpublished work, we have shown that miR-146b
expression can be clearly detected by reverse transcriptase qualitative polymerase chain
reaction in miR-146a-deficient bone marrow cells, indicating that it is not a pseudogene or
undetectable in adult hematopoietic cells as previously suggested (33, 50).
miR-146a functions in immunity
Our initial report showed that miR-146a is highly upregulated in human monocytes in a NF-
κB-dependent manner following Toll-like receptor (TLR) stimulation (4). Sequence
complementation-based algorithms (e.g. TargetScan) identified tumor necrosis factor
receptor (TNFR)-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase-1
(IRAK1) as the top predicted targets of miR-146a. The regulation of these two proteins by
miR-146a in monocyte/macrophages, T and B lymphocytes was then confirmed by 3′UTR
luciferase reporter assays and gene expression analyses (4, 33, 34, 36, 51). Because TRAF6
and IRAK1 are known feedback regulators of the NF-κB signaling pathway, a molecular
circuitry involving miR-146a, TRAF6/IRAK1, and NF-κB is proposed to be important in
the regulation of both innate and adaptive immunity (52). One of the first pieces of
definitive evidence of this hypothesis came from the study of miR-146a-deficient mice
generated in our laboratory (33). Consistent with the proposed hypothesis, miR-146a−/−
mice were found to be hyper-responsive to LPS challenge. Stimulation with sublethal level
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of LPS in vivo induced a higher serum level of pro-inflammatory cytokines, including
TNFα and IL-6 and IL-1β, in miR-146a−/− mice than in wildtype mice. In addition,
miR-146a−/− mice experienced a higher mortality rate in response to minimal lethal LPS
challenge. The hyper-inflammatory response was also observed in bone marrow-derived
macrophages (BMDMs) from miR-146a−/− mice in vitro. To complement the study on
miR-146a−/− mice, enforced overexpression of miR-146a in THP-1 cells resulted in an
attenuated inflammatory response (33). Work of others has confirmed these general
observations. These studies provide further support that miR-146a is an important negative
regulator of innate immune activation, potentially by targeting TRAF6 and IRAK1 and by
orchestrating the silencing of TNFα gene in human monocytic cell lines in the context of
endotoxin-induced tolerance (53–55).
miR-146a as effector of monocyte/macrophage function
In addition to regulating pro-inflammatory cytokine production, miR-146a negatively
regulates type I IFN production in vesicular stomatitis virus-infected mouse peritoneal
macrophages by targeting TRAF6, IRAK1, and IRAK2 through a RIG-I/NF-κB-dependent
but TLR4/MyD88-independent pathway (36). A study in human peripheral blood
mononuclear cells confirmed a role for miR-146a as a negative regulator of the type I IFN
pathway (56). In a more elaborate example of cell-type-specific regulation by miR-146a in
the innate immune system, miR-146a specifically controls the Ly-6Chi but not Ly-6Clo
monocyte response during inflammatory challenge (31). The regulation by miR-146a in this
context is cell intrinsic, apparently through directly targeting Relb, thus also connecting
miR-146a to the noncanonical pathway of NF-κB activation. This study further substantiates
the role of miR-146a in innate immunity by controlling monocyte functional heterogeneity
during an inflammatory response. Given the hyperinflammation and the exaggerated
immune response in the absence of miR-146a, we would expect miR-146a−/− mice to be
more resistant to bacterial infection than wildtype animals. Indeed, miR-146a−/− mice
displayed a lower bacterial load upon infection with Listeria monocytogenes (31).
Functional role of miR-146a in T cells
The role of miR-146a in adaptive immunity is particularly well studied in T cells. Aging
miR-146a−/− mice develop an autoimmune disorder with lymphadenopathy, lymphocyte
infiltration in various organs, and an activated T-cell phenotype (33). We carried out
detailed analysis in a subsequent study to understand the physiological role of miR-146a in
regulating the T-cell response to antigen stimulation (34). We showed that miR-146a-
deficient CD4+ and CD8+ T cells are hyper-responsive following T-cell receptor (TCR)
stimulation, as indicated by increased proliferation and survival, exaggerated activation
phenotype, and enhanced effector cytokine production. The regulation of cell-intrinsic T-cell
response upon TCR stimulation by miR-146a was shown to again be through the regulation
of TRAF6/IRAK1 and NF-κB signaling. This study adds miR-146a to a list of well-known
negative regulators of NF-κB, including IκBα and A20, acting following TCR activation
and suggests that these feedback regulators function collaboratively to limit the extent and
timing of activation, with each apparently fulfilling a crucial non-redundant role. These mice
studies were supported by studies in human T cells showing that miR-146a overexpression
impairs IL-2 production. However, contrary to our observation that TCR-induced apoptosis
was reduced in miR-146a-deficient T cells and enhanced in T cells with miR-146a
overexpression, activation-induced cell death seems to be inhibited by miR-146a
overexpression in human Jurkat T-cell cancer line (40). The discrepancy may be due to the
differences between mouse primary T cells and human cancer cell lines or the level of
miR-146a overexpression achieved in the two experimental systems.
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In addition to functioning in effector T cells in a cell-intrinsic manner, miR-146a also
controls the regulation of T-helper 1 (Th1) responses by affecting regulatory T-cell (Treg)-
function (57). Treg cells maintain immune homeostasis by suppressing the inflammatory
response and preventing an overreaction. In Treg cells, expression of miR-146a, but not
miR-146b, is much higher than that in naive T cells. In turn, miR-146a-deficient Treg cells
are functionally defective in their ability to restrain effector T cells, leading to
overproduction of IFNγ and autoimmunity. Stat1 appears to be a responsible target for
miR-146a in regulating Treg cells. This study revealed an important regulatory function of
miR-146a in Treg cells, suggesting upregulation of miR-146a is required for Treg cells to
properly control the IFNγ-mediated Th1 response. The results imply an interesting
phenomenon, which is that excessive effector cytokine signaling in Treg cells can lead to
their failure to suppress the corresponding cytokine response in effector T cells. Further
studies are required to elucidate the mechanistic implications behind this type of Treg cell/
effector T-cell regulation.
miR-146a in B cells
Our knowledge of the function of miR-146a in B cells is limited. One study has provided
evidence for miR-146a induction in a NF-κB-dependent manner by Epstein-Barr virus latent
membrane protein 1 (LMP1) in human B lymphocytes (38). Study from miR-146a-deficient
mice suggested that B cells in these mice are also hyperactivated and autoreactive, because
we can detect anti-double stranded DNA (anti-dsDNA) antibodies in the serum and a small
percentage of B-cell lymphomas in aging miR-146a−/− mice (33, 58). We have also seen de-
repression of TRAF6 and IRAK1 by Western blot in splenic B cells from miR-146a−/− mice
(33). Further studies will be required to understand the function of miR-146a in B cells.
Functions of miR-146a in hematopoiesis: effect of miR-146a in megakaryopoiesis
In addition to the functional role of miR-146a within immune cells, miR-146a also is
important for regulating the development of hematopoietic cells. Consistent with its
expression pattern, miR-146a plays a role in the development of a wide spectrum of
hematopoietic cells. An early in vitro study using human leukemic cell lines and CD34+
progenitor cell culture suggested a role for miR-146a in megakaryopoiesis, during which
upregulation of the transcription factor PLZF represses miR-146a expression, which in turn
leads to increased expression of a direct target of miR-146a, CXCR4. In this study (41),
overexpression of miR-146a led to impaired megakaryocytic proliferation, differentiation,
and maturation. However, the cell-autonomous regulation of miR-146a in megakaryopoiesis
is challenged by a later study, which showed no detectable changes in megakaryocyte
development and platelet activation properties by overexpression of miR-146a in all
hematopoietic cells in mice (59). This discrepancy may be a consequence of differences
between the two experimental systems, an in vitro study with human cells versus a mouse in
vivo system. Nevertheless, the study done with an overexpression system does not exclude a
role for miR-146a in megakaryopoiesis, because miR-146a expression is upregulated during
megakaryopoiesis and the endogenous level of miR-146a may be sufficient to downregulate
the relevant target genes to ensure normal megakaryocyte development. In contrast,
knocking down miR-146a and miR-145 concurrently with a ‘sponge’ in mouse
hematopoietic stem and progenitor cells (HSPCs) leads to megakaryocyte expansion and
thrombocytosis in vivo. However, this effect may be indirectly mediated by increased
production of the positive acting cytokine IL-6 from miR-146a-deficient myeloid and
lymphoid cells (51). In contrast, significant reduction in platelet counts is frequently seen in
aging but not in young miR-146−/− mice (33, 58). The observed thrombocytopenia in aging
miR-146a−/− is a manifestation of bone marrow failure and fibrosis or chronic dysregulation
of inflammatory cytokine production. Overall, miR-146a has a regulatory function in
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megakaryopoiesis in a cell-intrinsic manner and/or by controlling the inflammatory
environment.
miR-146a in myeloid development
The involvement of miR-146a in myeloid development is particularly interesting. Stable
knockdown of both miR-145 and miR-146a concurrently in mouse HSPCs results in
variable neutropenia and decreased colony-forming ability of bone marrow cells (51). In
support of miR-146a as the dominant miRNA in this effect, overexpression of TRAF6, a
validated target of miR-146a, also leads to mild neutropenia, with a subset of mice
progressing to marrow failure or acute myeloid leukemia (51). More conclusive data came
from the subsequent analysis of miR-146a−/− mice. MiR-146a−/− mice are born at the
expected Mendalian frequency and show no detectable phenotype during the first 2 months
of their life in the absence of an inflammatory or infectious challenge. This suggests that
miR-146a is not an essential gene for the proper development of blood lineages under steady
state in young mice. However, with natural aging, miR-146a−/− mice develop a progressive
myeloproliferative phenotype in both spleen and bone marrow. Specifically, there is a
significant increase in the percentage of CD11b+ cells in their spleens and bone marrows. It
can readily be detected by FACS analysis of 6-month-old miR-146a−/− mice. The myeloid
expansion becomes progressively larger by 12 months, as indicated by more than a threefold
increase in the CD11b+ percentage and more than a 10-fold increase in the total number of
CD11b+ cells in spleens. Bone marrows of these mice are also dominated by myeloid cells,
representing close to 80% of all bone marrow cells (33, 58). Bone marrow-derived
macrophages (BMDMs) developed from young knockout mice also proliferate faster in
response to macrophage colony-stimulating factor (M-CSF). Consistent with this
observation, increased surface expression of CSF1R, the receptor for M-CSF, is also
detected in the knockout spleen, bone marrow, and peripheral blood myeloid cells (33, 58).
In addition, miR-146a deficiency also confers a proliferative advantage on Ly-6Chi
monocytes in bone marrow, spleen, and the peritoneal cavity in inflammatory conditions
(31). Mechanistically, miR-146a−/− spleen and bone marrow cells exhibit increased
transcription of NF-κB-responsive genes. Increased NF-κB p65 translocation to the nucleus
is also evident in miR-146a−/− spleen cells. The increased myeloproliferation is dependent
on the activation of NF-κB, because genetic ablation of an important subunit of NF-κB, p50,
suppresses myeloproliferation (58). Study pursuing the mechanism of NF-κB-driven
myeloproliferation will help shed further insight on the molecular link between chronic
inflammation and hematopoietic malignancy.
Enforced expression of miR-146a in bone marrow transplant studies in mice has produced
inconsistent results. One study reported that overexpression of miR-146a in 5-fluorouracil
(5-FU) treated bone marrow cells results in a transient myeloid expansion that subsequently
returns to normal (35). Another report showed no detectable change in circulating
granulocytes, T cells, and B cells by overexpressing miR-146a in lineage negative bone
marrow cells (59). Lastly, one other group showed that ectopic expression of miR-146a in
sorted LKS (lineage−cKit+Sca1+) cells directs the selective differentiation of HSCs into
peritoneal macrophages in mice. Surprisingly, other than the peritoneal cavity, this study
failed to detect any transplanted miR-146a-expressing donor cells in the peripheral blood,
spleen, and bone marrow, precluding comparison in these hematopoietic compartments with
the other overexpression studies. The same report (39) also showed that inhibition of
miR-146a impairs macrophage formation during early zebrafish development. In addition to
different investigators overexpressing miR-146a in different fractions of bone marrow cells,
it is also unclear whether the levels of miR-146a overexpression achieved were comparable
between these studies. Despite some inconsistent findings, it appears that enforced
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expression of miR-146a in mouse bone marrow cells has an overall minor effect on
hematopoiesis, at least in the major hematopoietic organs under steady state.
The Yin of miRNA-146a: involvement in immune system pathology
Overview of miRNA-146a in pathology
The importance of miR-146a is further exemplified by its extensive involvement in
immunological pathologies, including autoimmunity and hematologic malignancy. Loss-of-
function studies in mice have provided some important insight in the role of miR-146a in the
pathogenesis of autoimmunity. Genetic deletion of miR-146a in all the cells in mice leads to
autoimmunity, indicated by splenomegaly, lymphadenopathy, lymphocyte-infiltration in
liver, kidney, and lung, and the development anti-dsDNA antibodies (33). The contribution
of miR-146a to autoimmunity occurs in at least three separate ways: (i) regulation of
miR-146a in effector T cells, (ii) regulation of miR-146a in Treg cells, and (iii) regulation of
myeloid cell-mediated inflammation. MiR-146a-deficient T-effector cells contribute to
autoimmunity in a cell-intrinsic manner. MiR-146a-deficeint T cells remain hyper-
responsive to antigen stimulation when adoptively transferred into wildtype mice and they
induce a spontaneous autoimmune pathology when transferred into Rag1−/− mice.
Mechanistically, the enhanced proliferation, impaired activation-induced apoptosis, and
exaggerated effector cytokine production seen in miR-146a-deficient CD4+ and CD8+ T
cells derive from uncontrolled NF-κB activation as a result of de-repressed TRAF6 and
IRAK1 (34). Whether the multi-organ autoimmune pathology is caused by a general
overactivation of miR-146a-deficient T cells or by a more specific autoreactivity against a
particular cell type or self-antigen remains an interesting unanswered question. In addition,
miR-146a-deficient Treg cells are also functionally defective in suppressing excessive Th1
response. In the absence of miR-146a, upregulation of signal transducer and activator of
transcription 1 (STAT1) in Treg cells is responsible for the failure to suppress wildtype
effector T cells, leading to fatal IFNγ-mediated autoimmunity in a variety of organs (57).
The chronic inflammatory environment conditioned by miR-146a-deficient myeloid cells
also contributes to autoimmune pathology by further stimulating T cells and promoting
tissue damage (33, 58). Lastly, anti-dsDNA antibodies are present in the serum of aging
miR-146a−/− mice (33). Future studies examining of the role of miR-146a in B cells may
yield additional insight into the regulation of autoantibody production. Given the widespread
expression of miR-146a outside of hematopoietic cells, miR-146a may exert protective
function in non-hematopoietic tissues. Evidence supporting this comes from studies on lung
epithelial cells and neonate guts (60, 61). Interestingly, during the dramatic transition from a
sterile environment to a bacteria-colonized surface in neonate guts, sustained miR-146a
expression seems to be critical to mediate innate immune tolerance by repressing IRAK1
(60). In light of this observation, we speculate that miR-146a deficiency in intestinal
epithelial cells may lead to intestinal inflammation, contributing to the overall autoimmune
pathology in miR-146a−/− mice.
Corroborating the in vivo studies in mice, miR-146a has been found to be extensively
dysregulated in human patients with autoimmune diseases, including systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA). In lupus patients, miR-146a expression
is downregulated in peripheral blood mononuclear cells (PBMCs). In addition, the level of
miR-146a expression is negatively correlated with disease severity, with lower expression
correlating with more active disease and proteinuria symptoms (56). Type I IFN is suggested
to be the responsible pathway upregulated in lupus, and additional targets of miR-146a,
IRF5, and STAT1 have been identified based on 3′UTR luciferase reporter assay and
Western blot analysis in 293T cells overexpressing miR-146a. Interestingly, enforced
expression of miR-146a in PBMCs of lupus patients can downregulate a subset of IFN-
responsive genes (56). Additional evidence comes from genome-wide association studies
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that identified SNPs (single-nucleotide polymorphisms) in the regulatory region of
miR-146a that are associated with lupus disease risk (62, 63). One such SNP (rs57095329)
in the promoter region of miR-146a is associated with the binding strength of transcription
factor Ets-1, another lupus-susceptibility gene. The risk-associated G allele in this SNP
correlates with reduced Ets-1 binding and decreased miR-146a expression (63).
In contrast to SLE where miR-146a expression is shown to be downregulated,
overexpression of miR-146a is frequently detected in rheumatoid arthritis (RA) patients (64–
66). miR-146a also seems to be highly expressed in osteoarthritis cartilage (67). Despite that
both SLE and RA are autoimmune diseases with some shared characteristics, the underlying
etiologies may be distinct. For example, chronic inflammation is a shared pathology, but the
dysregulated cytokine profiles are different between SLE and RA. The IFN pathway is
intimately linked to the pathogenesis of SLE, while increased TNFα, IL-1β, and IL-6
production are more prominent features of RA (64). Because pro-inflammatory cytokines
can significantly upregulate miR-146a expression in various cell types, increased miR-146a
expression may simply reflect the hyper-inflammatory environment and may be a useful
marker for disease severity in RA. However, miR-146a deficiency may be causally related
to the pathogenesis of SLE. It will be interesting to further investigate the involvement of
miR-146a deficiency in the development and progression of SLE and a number of other
autoimmune diseases and whether upregulation of miR-146a may have therapeutic benefit in
mouse models and human clinical samples. In the addition to the role of miR-146a in Th1
cells, Treg cells, and monocyte/macrophages, understanding the function of miR-146a in
Th17 cells (68), a key cell type in a number of autoimmune diseases, may provide additional
insight on this miRNA’s involvement in autoimmunity.
There is also some evidence suggesting a role of miR-146a in atherosclerosis, a less studied
aspect of miR-146a biology. Two reports (69, 70) suggested that upregulation of miR-146a
may inhibit atherosclerosis by suppressing TLR4 and CD40L expression in low-density
lipoprotein-induced macrophages and dendritic cells.
miRNA-146a in hematologic malignancy
Recent studies have also revealed an important role of miR-146a in hematologic pre-
malignancy and malignancy, most notably myelodysplastic syndromes (MDS),
myeloproliferative disease, myeloid cancer, and bone marrow failure. MDS represent a
heterogeneous group of clonal diseases of HSC origin characterized by ineffective
hematopoietic differentiation, peripheral blood cytopenias, bone marrow dysplasia, and a
propensity to progress to leukemia and bone marrow failure. Recent studies have made
significant advances on the molecular pathogenesis of MDS, including dysregulated
expression of miRNAs (71–73). Starczynowski et al. (51) have shown that two miRNAs,
miR-145 and miR-146a, are located in or near the commonly deleted region of 5q-
syndrome, a common subtype of MDS. Accordingly, expression of these two miRNAs is
reduced in patients of 5q- syndrome. The same study also showed that the stable knockdown
of miR-145 and miR-146a concurrently in mouse HSPCs recapitulates many of the key
features of human 5q- syndrome, including thrombocytosis, megakaryocytic dysplasia, and
mild neutropenia. In addition, overexpression of TRAF6, a target of miR-146a, was
sufficient to phenocopy many of the features of knocking down miR-145 and miR-146a,
suggesting that miR-146a may be a more dominant miRNA. Studies with miR-146a
knockout mouse are reaffirming. With increasing age, miR-146a−/− mice develop myeloid
expansion in spleen and bone marrow, pancytopenia in the periphery, and a propensity to
progress to bone marrow failure and myeloid cancer, a constellation of features reminiscent
of a mixed myelodysplastic syndrome and myeloproliferative neoplasm (MDS/MPN) (33,
58). Mechanistically, increased NF-κB activation is a main driver of the myeloproliferative
and bone marrow failure phenotype, because ablation of the p50 subunit greatly reduces
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MDS/MPN symptoms. It is now increasingly appreciated that a distinct hematopoietic
developmental program, termed inflammatory hematopoiesis, is activated in bone marrow
during inflammation to promote myelopoiesis at the expense of lymphopoiesis and
erythropoiesis (74). We speculate that uncontrolled and persistent inflammatory
hematopoiesis may promote pathological features of MDS and MPN, and over time, the
pathologic hematopoietic program becomes permanent and irreversible through additional
genetic mutations and/or epigenetic changes. Because chronic inflammation is a prominent
feature of miR-146a−/− mice during stimulation and aging, it will be interesting to
investigate whether miR-146a may serve as a molecular link between chronic inflammation
and hematopoietic malignancy, such as MDS and MPN. In addition to myeloid cancers,
about 15% of miR-146a−/− mice also develop B-cell or mixed B and T-cell lymphomas by
18 to 24 months (58). It is not clear whether the mechanism underlying lymphoma
development in miR-146a-deficient mice is distinct from the one driving myeloid
oncogenesis.
Many groups have extensively profiled miRNA expression in human leukemia in an effort
to identify microRNA signatures associated with leukemia diagnosis, prognosis, and
pathogenesis. Reports from different groups have identified miR-146a downregulation in
CD34+ cells or total bone marrow cells from patients with 5q- syndrome (26, 51, 73).
However, miR-146a downregulation is not consistently observed in leukemia studies. One
expression profiling study showed that miR-146a is downregulated in bone marrow cells of
AML patients compared to normal CD34+ cells (75). However, in another study that
compared miRNA expression between AML and ALL samples, increased expression of
miR-146a in both ALL and AML was shown to correlate with poor survival (76). miR-146a
was also shown to function as a tumor suppressor in natural killer/T-cell lymphoma, and
reduced expression of miR-146a was identified as a poor prognostic factor (77). It seems
miR-146a downregulation is a consistent feature of 5q- syndrome or even all MDS and may
be involved in the pathogenesis of MDS. The role of miR-146a in leukemia and lymphoma
requires further clarification.
Relationship between miR-146a and miR-155
MicroRNA-155 (miR-155) is another miRNA identified from our original screen for
miRNAs induced upon NF-κB activation (4). However, in contrast to miR-146a, miR-155
plays an almost exact opposite role in immunity and hematopoiesis. For more detailed
reviews of miR-155 biology, we refer you to recent reviews published elsewhere (50, 74,
78–80). Here we focus on the aspect of miR-155 function opposing that of miR-146a. NF-
κB activates an elaborate and potent transcription program central to inflammation and
immunity. Because of the potency of this pathway, proper regulation of the magnitude and
duration of NF-κB activation is essential (50, 81–83). NF-κB-induced miRNAs, miR-146a,
and miR-155 may be two important regulators that balance the negative and positive effects
driven by NF-κB activation. The opposing roles of miR-146a and miR-155 have been most
clearly demonstrated in the function and development of myeloid cells. While basal
expression of miR-155 is low in myeloid cells, many of the inflammatory stimuli that can
induce miR-146a expression, including TLR ligands and pro-inflammatory cytokines, also
upregulate miR-155 expression significantly (84, 85).
In regulating the functional capacity of myeloid cells, miR-155, upon induction, promotes
expression of pro-inflammatory cytokines and the IFN response. This regulation is most
likely through repression of suppressor of cytokine signaling 1 (SOCS1) and SH2 domain-
containing inositol phosphatase-1 (SHIP1), both negative regulators of the pro-inflammatory
pathways (86, 87). Consistent with this idea, inhibition of miR-155 in macrophages confers
tolerance to endotoxin shock in mice, while mice with miR-155 overexpression become
hypersensitive (87, 88). The exactly opposite effect has been observed with miR-146a
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inhibition and overexpression (33). In addition to pro-inflammatory cytokine production,
miR-146a and miR-155 also regulate immunity in the opposite manner. In general, mice
with targeted miR-155 deletion are immunocompromised, as indicated by attenuated
immune response to immunization and infection (89, 90). Inhibiting miR-146a may result in
a heightened immune response as shown by enhanced protection against Listeria infection
(31). miR-146a and miR-155 also have an opposite effect in regulating certain aspects of T-
cell function. As discussed above, miR-146a-deficient CD4+ T cells display a hyper-
activated response upon TCR stimulation, while miR-155-deficient CD4+ T cells are
attenuated in IL-2 and IFNγ cytokine production upon TCR stimulation (34, 89). Similarly,
miR-155 and miR-146a also function in an opposite direction in autoimmunity. Contrary to
miR-146a−/− mice that are prone to developing autoimmune disease, miR-155−/− mice were
shown to be significantly resistant to an induced model of experimental autoimmune
encephalomyelitis (EAE) because of a deficit in inflammatory T-cell development and, to a
lesser extent, a defect in myeloid dendritic cell function (91). In a recent effort to directly
study the opposing function of miR-146a and miR-155, mice deficient of miR-146a,
miR-155, or both miRNAs were implanted with subcutaneous solid tumors and were shown
to have differential ability to control tumor growth (92). This study showed again that in the
context of antitumor immunity, miR-146a and miR-155 play opposing roles; miR-155
promotes while miR-146a represses antitumor immunity, correlating their functions to
regulate IFNγ-producing CD4+ T-cell development.
As described above, miR-146a and miR-155 are concurrently upregulated in response to
pro-inflammatory cues. Data suggest that miR-146a and miR-155 may counterbalance each
other during inflammatory hematopoiesis. Sustained expression of miR-155 in mouse
HSPCs results in a myeloproliferative disorder, characterized by profound
myeloproliferation with dysplastic changes in the bone marrow, splenomegaly as a result of
extramedullary hematopoiesis, peripheral anemia, lymphopenia, and thrombocytopenia with
increased myeloid cells (84). The constellation of hematologic abnormalities seen in
miR-155-overexpressing mice is strikingly similar to the one observed in aging miR-146a-
deficient mice (58). miR-155-induced myeloproliferative disorder is thought to be primarily
through repressing SHIP1 (86). In addition, overexpression of miR-155 in a B-cell-specific
manner in a transgenic mouse model with E(mu)-promoter-driven miR-155 expression
results in B-cell leukemia and lymphoma (93). Similar B-cell lymphoma pathology has also
been observed in a subset of aging miR-146a−/− mice (58).
Given the above evidence, it is tempting to speculate that miR-146a and miR-155 are
evolutionarily selected to function in a tug-of-war manner to properly control the magnitude
and duration of NF-κB activation. Balanced level and proper timing of miR-146a and
miR-155 expression represents one critical layer of regulation to ensure that NF-κB is
activated in a controlled manner.
Summary remarks
Intensive study of miR-125b and miR-146a have revealed both the Yin and Yang
characteristics of these microRNAs in the immune system. Whereas they regulate normal
function, including hematopoiesis and immunity, abnormal and unregulated expression of
these microRNAs contributes to myeloproliferative disorder and cancer.
miR-125b and miR-146a appear to share overlapping biological processes. In some cases,
they have similar impacts, whereas in others, they appear to have opposing effects. Both
miR-125b and miR-146a suppress T-cell activation and seemingly disfavor the B-cell axis.
However, the effect of these microRNAs on myeloid development and function is strongly
contrasting, with miR-125b enhancing macrophage inflammatory responses while miR-146a
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negatively regulates these processes. In sharp contrast, overexpression of miR-125b leads to
myeloid hyperproliferative disorder and hematopoietic cancer, whereas it is ablation of
miR-146a that induces similar events. The effects of miR-125b overexpression on these
disorders are rapid and observed in mice shortly after bone marrow reconstitution
experiments, suggesting that miR-125b may act directly on bone marrow cells to give rise to
these characteristics. By contrast, induction of myeloid proliferation and cancer following
ablation of miR-146a is a gradual process that has increasing impact as mice age, implying
that these events arise from chronic and progressive alterations in immune function. Because
of the involvement of the NF-κB pathway in this process, we speculate that continual low
grade inflammatory events in miR-146a−/− mice provide repeated, slowly resolved insults to
hematopoietic cells that subsequently cause irreversible cellular genetic mutations and/or
epigenetic changes, of which a frequent outcome is the development of cancer.
It is become increasingly clear that microRNAs have a major impact on many physiological
processes. It is thus expected that dysregulated expression of microRNAs would be closely
tied to specific pathologies. Targeting microRNAs could be an invaluable methodology for
the treatment of human disease, such as autoimmunity and leukemia.
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Fig. 1. Role of miR-125b in hematopoiesis
The figure displays a simplified diagram of the effect of miR-125b on hematopoietic
development and immune cell function. (A) miR-125b enhances the repopulation of
hematopoietic stem cells (HSCs). (B) miR-125b blocks the transition of common myeloid
progenitors (CLPs) to pro-B cells. (C) The development of effector T cells is inhibited by
miR-125b. (D) miR-125b drives the activation of macrophages. (E) Ectopic overexpression
of miR-125b increases the common myeloid progenitor (CMP) pool.
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Fig. 2. Expression of miR-146a is regulated by a set of transcriptional factors in a cell-lineage
specific manner, involving such factors as PU.1, c-ETS, and PLZF, and in an activation-
dependent manner, involving such factors as NF-κB
Validated targets of miR-146a include Irak1, Traf6, Stat1, and RelB, which are all involved
in the NF-κB and STAT pathways, highlighting the role of miR-146a as a critical negative
regulator of inflammatory and interferon signaling.
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Fig. 3. A simplified schematic depiction of hematopoietic tree highlighting the role of miR-146a
in hematopoiesis and immune cell function
(A). miR-146a negatively regulates myelopoiesis and myeloproliferation during
inflammation and aging. In the absence of miR-146a, increased myeloproliferation is
observed. (B). miR-146a negatively regulates megakaryopoiesis. Overexpression of
miR-146a inhibits megakaryocyte proliferation and differentiation, while downregulation of
miR-146a promotes megakaryocyte expansion and platelet production. However, in aging
miR-146a-deficient mice with bone marrow fibrosis, thrombocytopenia is observed.
MiR-146a is a negative regulator of monocyte and macrophage activation (C) and effector
T-cell activation (D). (E). In regulatory T cells, miR-146a positively controls Treg
functional competence. In the absence of miR-146a, Treg cells are defective in suppressing
effector T-cell activation.
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